Rheumatoid arthritis (RA) synovial tissue(ST) is an aggressive tissue replete with macrophages, lymphocytes, fibroblasts, and newly formed blood vessels. Monocyte/macrophages and fibroblasts are key producers of a number of cytokines thought to be responsible, in large part, for the inflammation and joint destruction found in the RA joint. For Instance, the investigator others have shown that these macrophages are important producers of the pro-inflammatory cytokines interleukin (IL)-8, monocyte chemo-attractant protein-1 (MCP-1), and growth related gene product gro-alpha. These cytokines act in concert to mediate Inflammation, in some cases angiogenesis (see Koch, et al., Science 1798, 1992), and the resultant joint destruction. While there are a number of existing therapies for RA, in many patients the disease process still is very severe, resulting in joint destruction, debilitation, and deformity. Mitigating cytokine production may help treat the disease process. In this proposal the applicants will examine the potential of two related antiinflammatory cytokines, IL-4 and IL-13 to downregulate inflammation using a gone therapy approach. IL-4 is a potent inhibitor of angiogenesis as well. Moreover, IL-4 and IL-13 have been shown to have a ben beneficial effect on an animal model of arthritis. The applicants will determine whether they can modulate both the course of pro-inflammatory cytokine production and arthritis in a rat adjuvant-induced arthritis model. They will initially optimize the gene delivery system using adenoviral vectors bearing lacZ. Finally, they will determine whether adenoviral vectors, bearing IL-4 or IL-13, mitigate RA inflammation and cytokine production in an RA ST-severe combined immunodeficient (SCID) mouse chimera. Additionally, this work, it is hoped, will lead to a better understanding of the requirements for gene therapy in RA with other anti-inflammatory genes. The applicants hope that use of gene therapy employing IL-4 or IL-13 genes will result in a promising new therapy for RA, which afflicts many patients each year.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI040987-03
Application #
6169972
Study Section
General Medicine A Subcommittee 2 (GMA)
Program Officer
Kirshner, Susan
Project Start
1998-05-01
Project End
2002-04-30
Budget Start
2000-05-01
Budget End
2001-04-30
Support Year
3
Fiscal Year
2000
Total Cost
$213,009
Indirect Cost
Name
Northwestern University at Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Amin, Mohammad A; Campbell, Phillip L; Ruth, Jeffrey H et al. (2015) A key role for Fut1-regulated angiogenesis and ICAM-1 expression in K/BxN arthritis. Ann Rheum Dis 74:1459-66
Tsou, Pei-Suen; Ruth, Jeffrey H; Campbell, Phillip L et al. (2013) A novel role for inducible Fut2 in angiogenesis. Angiogenesis 16:195-205
Isozaki, Takeo; Arbab, Ali S; Haas, Christian S et al. (2013) Evidence that CXCL16 is a potent mediator of angiogenesis and is involved in endothelial progenitor cell chemotaxis : studies in mice with K/BxN serum-induced arthritis. Arthritis Rheum 65:1736-46
Bank, Lisa M; Bianchi, Lynne M; Ebisu, Fumi et al. (2012) Macrophage migration inhibitory factor acts as a neurotrophin in the developing inner ear. Development 139:4666-74
Marotte, Hubert; Tsou, Pei-Suen; Rabquer, Bradley J et al. (2011) Blocking of interferon regulatory factor 1 reduces tumor necrosis factor ?-induced interleukin-18 bioactivity in rheumatoid arthritis synovial fibroblasts by induction of interleukin-18 binding protein a: role of the nuclear interferon regulatory factor 1 Arthritis Rheum 63:3253-62
Amin, M Asif; Rabquer, Bradley J; Mansfield, Pamela J et al. (2010) Interleukin 18 induces angiogenesis in vitro and in vivo via Src and Jnk kinases. Ann Rheum Dis 69:2204-12
Scatizzi, John C; Hutcheson, Jack; Pope, Richard M et al. (2010) Bim-Bcl-2 homology 3 mimetic therapy is effective at suppressing inflammatory arthritis through the activation of myeloid cell apoptosis. Arthritis Rheum 62:441-51
Marotte, Hubert; Ahmed, Salahuddin; Ruth, Jeffrey H et al. (2010) Blocking ERK-1/2 reduces tumor necrosis factor alpha-induced interleukin-18 bioactivity in rheumatoid arthritis synovial fibroblasts by induction of interleukin-18 binding protein A. Arthritis Rheum 62:722-31
Hou, Y; Rabquer, B J; Gerber, M L et al. (2010) Junctional adhesion molecule-A is abnormally expressed in diffuse cutaneous systemic sclerosis skin and mediates myeloid cell adhesion. Ann Rheum Dis 69:249-54
Ruth, Jeffrey H; Park, Christy C; Amin, M Asif et al. (2010) Interleukin-18 as an in vivo mediator of monocyte recruitment in rodent models of rheumatoid arthritis. Arthritis Res Ther 12:R118

Showing the most recent 10 out of 30 publications